Intercept Pharmaceuticals Receives $30,000,000 Series C Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6e85fb7e-c6db-4324-9e81-8f00964b6842&Preview=1 -
Date
8/13/2012 -
Company Name
Intercept Pharmaceuticals -
Mailing Address
18 Desbrosses Street New York, NY 10013 -
Company Description
Intercept Pharmaceuticals Inc., is a clinical stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases. -
Website
http://www.interceptpharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$30,000,000 -
Transaction Round
Series C -
Proceeds Purposes
This financing allows us to continue advancing our lead compound OCA in POISE, our Phase 3 PBC trial, while pursuing other therapeutic indications of interest. -
M&A Terms
-
Venture Investor
OrbiMed Advisors -
Venture Investor
OrbiMed Advisors -
Venture Investor
Genextra S.p.A. -
Venture Investor
Undisclosed
